High-pressure treatment reduces the immunoreactivity of the major allergens in apple and celeriac
โ Scribed by Fiona A. Husband; Thomas Aldick; Iesel Van der Plancken; Tara Grauwet; Marc Hendrickx; Isabel Skypala; Alan R. Mackie
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 238 KB
- Volume
- 55
- Category
- Article
- ISSN
- 1613-4125
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Scope: The impact of thermal and high pressure (HP) processing on the immunoreactivity of the allergens Mal d 1, Mal d 3 and Api g 1 has been investigated in apple and celeriac tissue, respectively.
Methods and results: The extracted proteins were assessed using SDSโPAGE and Western blot. The results showed that Mal d 1 was subject to loss of immunoreactivity as soon as the apple tissue was disrupted although it was remarkably resistant to both thermal and HP processing. This is in contrast to the Mal d 1 structural homolog from celeriac, Api g 1, that was susceptible to thermal processing. The other major allergen in apple, Mal d 3, was found to be resistant to chemical modification and thermal processing in apple, which is in contrast to behavior in solution. However, the combination of pressure and temperature significantly reduced its immunoreactivity. Pectin was found to protect Mal d 3 from thermal denaturation in solution and is a possible candidate for the protective effect of the fruit.
Conclusion: The conclusion to be drawn from these results is that the combination of HP and thermal processing is an effective method to reduce the allergenicity of both apple and celeriac.
๐ SIMILAR VOLUMES
## Abstract **BACKGROUND:** Peanut allergy is one of the most serious food allergies, and Ara h 2 is one of the most important peanut allergens as it is recognised by serum immunoglobulin E from more than 90% of peanutโallergic individuals. Dynamic highโpressure microfluidisation has been widely us
The development of mutations conferring drug resistance was investigated in 49 antiretroviralnaive asymptomatic HIV-1 subjects with CD4 + cell counts of 250-500/mm 3 given intermittent (6-week courses, 6 weeks apart) or continuous treatment with zidovudine (AZT) plus zalcitabine (ddC) over 54 weeks.